Advanced malaria treatment in pregnant women

• Autores: Mamo Feyissa
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 19, Nº. 5, 2017, págs. 6-6
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Introduction: Malaria during pregnancy is a major public health concern and an important contributor to maternal and infant morbidity and mortality in malariaendemic countries. Pregnant women are particularly susceptible to malaria, and in low transmission settings they have a greater risk of severe Plasmodium falciparum malaria. Reviewing treatment protocol of pregnant women can put clear demarcation between safe and unsafe drugs there by prevent occurrence of abortion, still, birth, miscarriage in general avoid teratogenicity effect of drugs on fetus.

    Objective: The general objective of this review was to describe malaria treatment for pregnant women and to provide clinicians with up-to-date, evidence-based information on the treatment of malaria in pregnancy.

    Method: In this review it was examined the available information on the safety of antimalarials in pregnancy, from both animal and human studies. A literature search was performed using Medline (April 2016). Keywords used were «severe malaria in pregnant women», «uncomplicated malaria in pregnant women», «complication of malaria in pregnant women pregnancy treatment», «pharmacotherapy», «antimalarials », «artesunate», «artemether», «artemether-lumefantrine», «atovaquone proguanil», «chloroquine», «clindamycin», «dihyroartemisinin-piperaquine», «melfoquine», «quinine», «primaquine». Reference lists of the articles identified were hand searched for additional articles. The search was limited to English language articles. Outcomes of interest included measures of efficacy in pregnancy, safety and resistance.

    Conclusion: most antimalaria drugs are safe for pregnant women in the therapeutic dose range of drugs. Currently lumifantrine-arthimeter (quartum) become the safest drug even though previously there were no any safety data on the drug. Doxycycline, halofantrine, tetracycline, and primaqine are not recommended for pregnant women